These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 1980182

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Overview of the safety profile of the H2-receptor antagonists.
    Hansten PD.
    DICP; 1990 Nov; 24(11 Suppl):S38-41. PubMed ID: 1980183
    [Abstract] [Full Text] [Related]

  • 4. Use of H2-receptor antagonists in children.
    Dimand RJ.
    DICP; 1990 Nov; 24(11 Suppl):S42-6. PubMed ID: 2270695
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Controlling gastric pH: the impact of newer agents on the critically ill patient.
    Earnest DL.
    DICP; 1990 Nov; 24(11 Suppl):S31-4. PubMed ID: 1980181
    [Abstract] [Full Text] [Related]

  • 7. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?
    Wade EE, Rebuck JA, Healey MA, Rogers FB.
    Intensive Care Med; 2002 Apr; 28(4):459-65. PubMed ID: 11967601
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and acid-suppressant properties of histamine2-receptor antagonists for the prevention of stress-related mucosal damage in critical care patients.
    Schentag JJ, Carter CA, Welage LS.
    DICP; 1989 Oct; 23(10 Suppl):S36-9. PubMed ID: 2573208
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety profile of H2-receptor antagonists: current status of famotidine.
    Levine JB.
    J Int Med Res; 1989 Oct; 17 Suppl 1():48A-53A. PubMed ID: 2566543
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Histamine H2 receptor blockaders: possibilities and prognosis in the use of stage III-IV preparations in the therapy of internal diseases].
    Miagkova LP, Grebenev AL, Kkhorshed AM.
    Klin Med (Mosk); 1991 Mar; 69(3):27-34. PubMed ID: 1676773
    [No Abstract] [Full Text] [Related]

  • 17. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
    Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE.
    Aliment Pharmacol Ther; 1990 Mar; 4 Suppl 1():29-45. PubMed ID: 1983345
    [Abstract] [Full Text] [Related]

  • 18. Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.
    Thomas JM, Misiewicz G.
    Clin Gastroenterol; 1984 May; 13(2):501-41. PubMed ID: 6146417
    [No Abstract] [Full Text] [Related]

  • 19. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
    Adachi K, Komazawa Y, Mihara T, Azumi T, Fujisawa T, Katsube T, Furuta K, Kinoshita Y.
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
    [Abstract] [Full Text] [Related]

  • 20. Stress-related mucosal damage: review of drug therapy.
    Vorder Bruegge WF, Peura DA.
    J Clin Gastroenterol; 1990 Jul; 12 Suppl 2():S35-40. PubMed ID: 1978844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.